Search results
Non-Blanching Rash: Causes and When to Call a Healthcare Provider
Verywell Health via Yahoo News· 6 days agoNon-blanching rashes are caused by broken blood vessels beneath the surface of the skin. Often, the...
Chronic Myelogenous Leukemia (CML): 5 Things to Know
Medscape· 6 days agoAdvanced and emerging therapies in CML offer significantly improved survival. These five things to know will help elucidate potential pitfalls and pearls...
What Is Red Ear Syndrome (RES)?
Verywell Health via Yahoo News· 2 days ago...younger individuals Variable occurrence Onset with migraine headache either during the prodromal phase (the phase between initial symptoms and full...
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? - Cullinan Therapeutics...
Benzinga· 4 days agoExplore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on...
Breast cancer survivors have higher risk for other cancers
UPI· 3 days agoFemale breast cancer survivors were found to have an 87% higher odds of developing endometrial...
Patient tests positive for measles in Morgantown
WDTV· 6 days agoWVU Hospitals announced today (April 22) that an adult patient who had presented at an outpatient clinic last week has since tested positive for measles (rubeola). Upon receiving confirmation ...
Zelensky reminds world of Russian nuclear threat on Chornobyl anniversary
Kyiv Independent via Yahoo News· 2 days agoThe Zaporizhzhia plant – the largest nuclear plant in Europe – has been under Russian occupation...
Aamjiwnaang First Nation declares state of emergency declared over benzene levels
CBC via Yahoo News· 3 days agoAamjiwnaang First Nation in southwestern Ontario has declared a state of emergency over what it...
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation...
Digital Journal· 4 days agoIts safety and efficacy have not been established. The development of pelabresib was funded in part by The Leukemia and Lymphoma Society ® . About MANIFEST-2 MANIFEST-2 (NCT04603495 ...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric...
Fort Wayne Journal Gazette· 5 days agoNovartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera®...
